Cholera Toxin and Escherichia Coli Heat-labile Enterotoxin, but Not Their Nontoxic Counterparts, Improve the Antigen-presenting Cell Function of Human B Lymphocytes

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 2009 Feb 19

PMID 19223474

Citations 18

Authors

Donatella R M Negri

Dora Pinto

Silvia Vendetti

Mario Patrizio

Massimo Sanchez

Antonella Riccomi

Paolo Ruggiero

Giuseppe Del Giudice

Maria Teresa De Magistris

Affiliations

Soon will be listed here.

Abstract

B lymphocytes play an important role in the immune response induced by mucosal adjuvants. In this study we investigated the in vitro antigen-presenting cell (APC) properties of human B cells upon treatment with cholera toxin (CT) and Escherichia coli heat-labile enterotoxin (LT) and nontoxic counterparts of these toxins, such as the B subunit of CT (CT-B) and the mutant of LT lacking ADP ribosyltransferase activity (LTK63). Furthermore, forskolin (FSK), a direct activator of adenylate cyclase, and cyclic AMP (cAMP) analogues were used to investigate the role of the increase in intracellular cAMP caused by the A subunit of CT and LT. B lymphocytes were cultured with adjuvants and polyclonal stimuli necessary for activation of B cells in the absence of CD4 T cells. Data indicated that treatment with CT, LT, FSK, or cAMP analogues, but not treatment with CT-B or LTK63, upregulated surface activation markers on B cells, such as CD86 and HLA-DR, and induced inhibition of the proliferation of B cells at early time points, while it increased cell death in long-term cultures. Importantly, B cells treated with CT, LT, or FSK were able to induce pronounced proliferation of both CD4(+) and CD8(+) allogeneic T cells compared with untreated B cells and B cells treated with CT-B and LTK63. Finally, only treatment with toxins or FSK induced antigen-specific T-cell proliferation in Mycobacterium tuberculosis purified protein derivative or tetanus toxoid responder donors. Taken together, these results indicated that the in vitro effects of CT and LT on human B cells are mediated by cAMP.

Citing Articles

Nanoparticles and Antiviral Vaccines.

Liu S, Hu M, Liu X, Liu X, Chen T, Zhu Y Vaccines (Basel). 2024; 12(1).

PMID: 38250843 PMC: 10819235. DOI: 10.3390/vaccines12010030.

SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines.

Sunagar R, Singh A, Kumar S Vaccines (Basel). 2023; 11(4).

PMID: 37112761 PMC: 10143972. DOI: 10.3390/vaccines11040849.

Route and antigen shape immunity to dmLT-adjuvanted vaccines to a greater extent than biochemical stress or formulation excipients.

Stone A, Rambaran S, Trinh I, Estrada M, Jarand C, Williams B Vaccine. 2023; 41(9):1589-1601.

PMID: 36732163 PMC: 10308557. DOI: 10.1016/j.vaccine.2023.01.033.

GPR174 signals via Gs to control a CD86-containing gene expression program in B cells.

Wolf E, Howard Z, Duan L, Tam H, Xu Y, Cyster J Proc Natl Acad Sci U S A. 2022; 119(23):e2201794119.

PMID: 35639700 PMC: 9191659. DOI: 10.1073/pnas.2201794119.

Attacking the Intruder at the Gate: Prospects of Mucosal Anti SARS-CoV-2 Vaccines.

Karczmarzyk K, Kesik-Brodacka M Pathogens. 2022; 11(2).

PMID: 35215061 PMC: 8876505. DOI: 10.3390/pathogens11020117.

References

Arce S, Nawar H, Muehlinghaus G, Russell M, Connell T . In vitro induction of immunoglobulin A (IgA)- and IgM-secreting plasma blasts by cholera toxin depends on T-cell help and is mediated by CD154 up-regulation and inhibition of gamma interferon synthesis. Infect Immun. 2007; 75(3):1413-23. PMC: 1828582. DOI: 10.1128/IAI.01367-06. View

Rodriguez-Pinto D, Moreno J . B cells can prime naive CD4+ T cells in vivo in the absence of other professional antigen-presenting cells in a CD154-CD40-dependent manner. Eur J Immunol. 2005; 35(4):1097-105. DOI: 10.1002/eji.200425732. View

Majumdar S, Aggarwal B . Adenosine suppresses activation of nuclear factor-kappaB selectively induced by tumor necrosis factor in different cell types. Oncogene. 2003; 22(8):1206-18. DOI: 10.1038/sj.onc.1206184. View

Hoft D, Eickhoff C, Giddings O, Vasconcelos J, Rodrigues M . Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming. J Immunol. 2007; 179(10):6889-900. DOI: 10.4049/jimmunol.179.10.6889. View

Bagley K, Abdelwahab S, Tuskan R, Fouts T, Lewis G . Cholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway. Infect Immun. 2002; 70(10):5533-9. PMC: 128358. DOI: 10.1128/IAI.70.10.5533-5539.2002. View

Lycke N, Severinson E, Strober W . Molecular effects of cholera toxin on isotype differentiation. Immunol Res. 1991; 10(3-4):407-12. DOI: 10.1007/BF02919732. View

Lomo J, Blomhoff H, Beiske K, Stokke T, Smeland E . TGF-beta 1 and cyclic AMP promote apoptosis in resting human B lymphocytes. J Immunol. 1995; 154(4):1634-43. View

Myklebust J, Josefsen D, Blomhoff H, Levy F, Naderi S, Reed J . Activation of the cAMP signaling pathway increases apoptosis in human B-precursor cells and is associated with downregulation of Mcl-1 expression. J Cell Physiol. 1999; 180(1):71-80. DOI: 10.1002/(SICI)1097-4652(199907)180:1<71::AID-JCP8>3.0.CO;2-N. View

Nashar T, Betteridge Z, Mitchell R . Evidence for a role of ganglioside GM1 in antigen presentation: binding enhances presentation of Escherichia coli enterotoxin B subunit (EtxB) to CD4(+) T cells. Int Immunol. 2001; 13(4):541-51. DOI: 10.1093/intimm/13.4.541. View

10.

Johnson K, Davis B, Smith K . cAMP antagonizes interleukin 2-promoted T-cell cycle progression at a discrete point in early G1. Proc Natl Acad Sci U S A. 1988; 85(16):6072-6. PMC: 281907. DOI: 10.1073/pnas.85.16.6072. View

11.

Rappuoli R, Pizza M, Douce G, Dougan G . Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today. 1999; 20(11):493-500. DOI: 10.1016/s0167-5699(99)01523-6. View

12.

Vendetti S, Riccomi A, Sacchi A, Sciaraffia E, Gatta L, Pioli C . Inhibition of T cell proliferation by cholera toxin involves the modulation of costimulatory molecules CTLA-4 and CD28. Immunol Lett. 2007; 115(1):59-69. DOI: 10.1016/j.imlet.2007.10.003. View

13.

Liu Y, Barthelemy C, de Bouteiller O, Arpin C, Durand I, Banchereau J . Memory B cells from human tonsils colonize mucosal epithelium and directly present antigen to T cells by rapid up-regulation of B7-1 and B7-2. Immunity. 1995; 2(3):239-48. DOI: 10.1016/1074-7613(95)90048-9. View

14.

Kawamura Y, Kawashima R, Shirai Y, Kato R, Hamabata T, Yamamoto M . Cholera toxin activates dendritic cells through dependence on GM1-ganglioside which is mediated by NF-kappaB translocation. Eur J Immunol. 2003; 33(11):3205-12. DOI: 10.1002/eji.200324135. View

15.

Agren L, Ekman L, Lowenadler B, Nedrud J, Lycke N . Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J Immunol. 1999; 162(4):2432-40. View

16.

Verweij W, de Haan L, Holtrop M, Agsteribbe E, Brands R, van Scharrenburg G . Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Vaccine. 1998; 16(20):2069-76. DOI: 10.1016/s0264-410x(98)00076-0. View

17.

Bernasconi N, Traggiai E, Lanzavecchia A . Maintenance of serological memory by polyclonal activation of human memory B cells. Science. 2002; 298(5601):2199-202. DOI: 10.1126/science.1076071. View

18.

Yamamoto S, Takeda Y, Kurazono H, Imaoka K, Yamamoto M, Fujihashi K . Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J Exp Med. 1997; 185(7):1203-10. PMC: 2196267. DOI: 10.1084/jem.185.7.1203. View

19.

Lycke N, Bromander A, Ekman L, Karlsson U, Holmgren J . Cellular basis of immunomodulation by cholera toxin in vitro with possible association to the adjuvant function in vivo. J Immunol. 1989; 142(1):20-7. View

20.

Heit A, Huster K, Schmitz F, Schiemann M, Busch D, Wagner H . CpG-DNA aided cross-priming by cross-presenting B cells. J Immunol. 2004; 172(3):1501-7. DOI: 10.4049/jimmunol.172.3.1501. View